CERo Therapeutics Holdings, Inc. (CERO)
OTCMKTS · Delayed Price · Currency is USD
0.0320
-0.0023 (-6.71%)
At close: Apr 27, 2026

CERO Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-19.92-8.3-7.29-0.67-0.54
Depreciation & Amortization
1.091.161.12--
Other Amortization
0.61----
Loss (Gain) From Sale of Investments
----0
Stock-Based Compensation
1.10.930.1--
Other Operating Activities
0.86-8.54-0.25-2.84-0.03
Change in Accounts Payable
1.930.261.281.640.02
Change in Income Taxes
---0.6-
Change in Other Net Operating Assets
-1.741.58-0.740.17-0.65
Operating Cash Flow
-16.08-12.92-5.79-1.09-1.2
Investment in Securities
0.5----
Other Investing Activities
---180.84-306
Investing Cash Flow
0.5--180.84-306
Short-Term Debt Issued
-0.41-0.65-
Long-Term Debt Issued
--0.61--
Total Debt Issued
-0.410.610.650.09
Short-Term Debt Repaid
--0.4---
Long-Term Debt Repaid
--0.02---
Total Debt Repaid
--0.42---0.09
Net Debt Issued (Repaid)
--0.010.610.65-
Issuance of Common Stock
5.744.810.01-315.21
Repurchase of Common Stock
----139.35-
Other Financing Activities
2.81-0.51-0.04--6.14
Financing Cash Flow
13.9213.730.57-138.7309.08
Net Cash Flow
-1.660.81-5.2241.041.88
Levered Free Cash Flow
-7.63-3.669.9-13.44-
Unlevered Free Cash Flow
-7.63-3.669.9-13.44-
Change in Working Capital
0.191.840.542.41-0.63
Source: S&P Global Market Intelligence. Standard template. Financial Sources.